Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
May 15, 2024
Earnings Call Speaker Segments
Operator
operatorHello, everyone, and welcome to the conference call covering Palatin's operating results for the third quarter of fiscal year 2024. <<operator_script>>. Please note that this call is being recorded. Before we get into our prepared remarks, I want to point out that anything stated by Palatin that is not a historical fact may constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be correct, and actual outcomes could differ materially from what is expected because of the various risks and uncertainties described in the company's latest filings with the Securities and Exchange Commission. We encourage you to weigh those risks and uncertainties carefully as you evaluate these forward-looking statements regarding Palatin's prospects. At this point, I'll hand the call over to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and welcome to Palatin's call covering the third quarter of fiscal year 2024. I'm Dr. Carl Spana, Palatin's CEO and President. Joining me today is Steve Wills, our Executive Vice President, Chief Financial Officer, and Chief Operating Officer at Palatin. At this point I'll hand things over to Steve, who'll provide the financial and operating update. Steve.
Stephen Wills
executiveThanks, Carl, and good morning, everyone. I'll walk through Palatin's financial results for the fiscal third quarter that closed on March 31, 2024. Turning to revenue: total revenue is made up of gross product sales of Vyleesi — net of allowances — plus accruals. After we completed the sale of the worldwide rights to Vyleesi for female sexual dysfunction to Cosette Pharmaceuticals for up to $171 million in December of 2023, Palatin recorded no product sales to pharmacy distributors during the quarter that ended March 31, 2024. In the quarter that ended March 31, 2023, gross product sales came to $3.4 million, with net product revenue of $1.2 million. Now on operating expenses: total operating expenses reached $9.2 million, versus $8.5 million in the same quarter a year earlier. That rise reflected heavier spending on our Melanocortin receptor programs, partly offset by the removal of selling expenses tied to Vyleesi. Moving to other income and expense: total other income and expense, net, is composed primarily of the change in fair value of warrant liabilities, which Palatin carried as a liability on the consolidated financial statements. That includes revisions to certain prior period amounts to correct the misstatement involving classifying warrants as equity rather than liability. To be clear, all of that has been cleaned up.
Stephen Wills
executiveThere’s no longer any liability reflection left. And moving ahead, once again, that line item has been cleaned up. Each quarter, the statement of operations was adjusted so that changes in the fair value of these warrants would be reflected. For the quarter ended — for the quarters ended March 31, 2024, and 2023, Palatin recorded a fair value adjustment gain of $0.4 million and a loss of $1.5 million, respectively. Turning to cash flows, net cash used in operations at Palatin came to $8.6 million, versus $1.4 million in the same period a year earlier. That rise stems primarily from working capital changes. On net loss, Palatin posted a net loss of $8.4 million, or $0.53 per common share, against a net loss of $8.7 million, or $0.76 per common share, in the comparable period last year. The decline versus the comparable quarter a year ago was primarily driven by a larger operating loss in fiscal 2024, offset by higher other income, which came mainly from changes in the fair value of the warrant liabilities. As for cash position, at March 31, 2024, Palatin had cash, cash equivalents and marketable securities of $10 million, compared with cash, cash equivalents and marketable securities of $9.5 million plus $2.3 million of accounts receivable at December 31, 2023, and compared with $5.5 million plus $1.3 million of accounts receivable at September 30, 2023.
Stephen Wills
executiveWe think our current cash, cash equivalents, and marketable securities will be enough to cover operating expenses and disbursements as we currently expect them, carrying us well into the second half of calendar year 2024. At this point, I'd like to hand the call back to Carl. Carl?
Carl Spana
executiveThank you, Steve. As you're aware, our emphasis has been on gaining a grasp of the biology and chemistry behind the Melanocortin system, aiming to create selective Melanocortin agonists across a range of indications. A growing portfolio of Melanocortin based therapeutics has come out of these research efforts. We have three clinical programs built on Melanocortin agonists, and assuming resources are available, we intend to begin enrollment in two new clinical programs by mid-2024. All of this stems from our highly productive research activities. Turning now to our PL9643 dry eye disease program, we shared the positive Phase 3 MELODY-1 results earlier this quarter. I want to call out a few of the key findings that set PL9643 apart from current therapies and that have both us and potential partners very excited. We observe excellent ocular tolerability and safety, essentially comparable to a dry — eye artificial tear. I don't believe any product out there, approved or in development, matches PL9643 when it comes to ocular tolerability. We observe rapid onset of efficacy for both signs and symptoms of dry eye disease, with the primary symptom endpoints of pain and 7 of 11 secondary symptom endpoints achieving statistical significance at two weeks, which was the earliest time point we evaluated.
Carl Spana
executiveWhat's really important is that we keep seeing multiple symptom endpoints get better across the entire 12 weeks of treatment. Maximal efficacy hasn't been achieved as of yet, and our belief is that with longer treatment in the Phase 3 program coming up, we will keep observing even more efficacy from PL9643. At present we are getting ready for the remaining clinical studies that will support a new drug application submission, and we expect that to start in the second half of enrollment in the second half of calendar '24, along with an upcoming Type C meeting with the FDA to talk over the remaining program studies that we need to conduct. Our Phase 2 study of oral PL8177, a selective melanocortin-1 receptor agonist, in ulcerative colitis patients remains on track for an interim assessment with data released in mid-2024. Supporting the development of oral PL8177 are preclinical studies showing that treatment with 8177 leads diseased colons to improve toward a healthy state and to resolve inflammation. Resolving inflammation instead of blocking it opens up the possibility of efficacy combined with significantly differentiated safety when treating ulcerative colitis and other types of inflammatory bowel disease. Breakout, our Phase 2 open label study of a melanocortin agonist in diabetic patients with kidney disease, is likewise on track for top line data release in mid-2024 as well.
Carl Spana
executiveI want to spend a moment walking through two fresh clinical programs that we intend to launch during this year. Both of these initiatives build on our deep knowledge of the chemistry and biology of the melanocortin-4 receptor agonist, each one carries solid clinical validation, and they target sizable markets that are hungry for new therapeutic choices. The first is a Phase 2 obesity trial built to enroll as many as 60 of those patients who are right now taking tirzepatide at 2.5 milligrams on a weekly basis. Safety plus greater efficacy of giving bremelanotide together with tirzepatide for weight reduction is what the primary endpoint assesses. A secondary endpoint is going to assess how well bremelanotide maintains weight loss in patients who have ceased tirzepatide use. The FDA has reviewed both the initial drug application and the protocol for this study, and we are cleared to start enrolling patients. To back this study and our obesity program broadly, we held a key opinion leader event not long ago called Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in treating obesity and weight loss maintenance. The speaker, Dr. from the University of Oklahoma, talked about combining Melanocortin -4 receptor agonists with tirzepatide in obese patients, the ongoing demand for novel obesity treatments, and the various applications of Melanocortin-4 receptor agonists when treating obesity and weight loss maintenance.
Carl Spana
executiveA link to the event recording is available on our website. Obesity drug treatment is now well established and expanding quickly. Our view is that you need multiple drugs, with differing mechanisms of action, that impact weight loss and, crucially, weight loss maintenance. We firmly believe that drugs aimed at the melanocortin receptor system will play a significant role in the future of obesity treatment and weight loss maintenance. Our broad expertise in designing and developing melanocortin agonists to treat obesity covers 2 clinical studies that were completed and published earlier. We are well positioned to lead in developing melanocortin-based therapeutics for weight loss and weight loss maintenance. In addition, we are planning a Phase 2 clinical study that evaluates co-administration of Bremelanotide with a PDE5 inhibitor in treating erectile dysfunction patients who have failed PDE5 inhibitor monotherapy. This clinical study will support the development program for a combination product, which is a Co-Formulation of Bremelanotide with a inhibitor and extends our commercial efforts in sexual dysfunction. Roughly 35% of men with erectile dysfunction fail or respond inadequately to PDE5 inhibitor treatments, and these include things like Cialis and Viagra. We represent a large underserved market.
Carl Spana
executiveWhen it comes to these failure patients, the sole treatment choices are highly invasive—things like direct penile injections or penile implants. Clinical studies we ran earlier demonstrated that pairing Bremelanotide with a PDE5 inhibitor produces synergistic effects when used to treat erectile dysfunction. I believe we are well positioned to run an efficient and successful development program for the Co-Formulated product. Here are the highlights for the third quarter of fiscal year 2024. We reported positive results from the PL9643 Phase 3 MELODY-1 dry eye disease clinical study, and PL9643 is emerging as a highly differentiated treatment for dry eye disease, with excellent ocular tolerability, rapid onset of efficacy and broad relief from multiple symptoms of dry eye disease. We plan to initiate two new Melanocortin programs with Phase 2 clinical studies that have data readouts in 2024. Finally, our clinical programs continue to advance, with multiple clinical data milestones from four clinical programs and the initiation of the remaining PL9643 Phase 3 studies by calendar year end. Steve and I want to thank you for listening to the Palatin third quarter fiscal year 2024 conference call. Additional information on our science and clinical programs is available on our website, www.palatin.com, and additional information on Vyleesi can be found at the vyleesi.com website.
Carl Spana
executiveWe appreciate it, and at this point we'll begin the Q&A portion and take your questions.
Operator
operatorOperator, our first question comes from Joe Pantginis at H.C. Wainwright & Co LLC.
Joe Pantginis
analystMorning, everyone, and thanks for taking my question. Steve and Carl, I'd like to zero in on the overall profile for 9643 as it stands right now. Following the MELODY-1 data, you have a Type C meeting coming up. What exactly are you hoping to clarify or reach agreement on when it comes to moving forward? And prior to receiving that feedback, has anything learned from MELODY-1 changed how you might potentially approach MELODY-2?
Carl Spana
executiveAbsolutely. I'll go through that in reverse sequence. Yes, that's correct. Clearly, MELODY-1 was an extremely big clinical trial, of course. A great deal of data came out of it, and as with most drug development efforts, you keep gaining knowledge while conducting these studies. You don't always end up with what you hoped for. But here's how we're framing it: we would like to run two additional trials, MELODY-2 and MELODY-3, to supply the remaining data we require. That approach gives us 3 large phase three clinical trials to firmly back the drug's profile, its safety, and its efficacy overall. And in our view, that's the wisest path forward. It's highly unusual for dry eye disease products to win approval based on only 2 studies. Typically, the majority of these programs rely on three, four, five Phase 3 studies to support their overall approval. So that's the strategy we're pursuing. What we've learned — I think, in addition, the endpoint concerning symptoms — will in all likelihood be ocular pain. But importantly, we truly want to keep emphasizing the broad efficacy we're observing on symptoms. I mean, we're seeing 8 symptoms out of the 11 measured all reach significance beginning at 2 weeks and then continuing from there.
Carl Spana
executiveNothing available on the market delivers that kind of symptom relief. So we truly want to ensure these studies make that point clearly. Beyond that, we need to secure the sign. The sign is really a regulatory endpoint. And I believe we've worked out how to accomplish that — when to take the measurement, what to measure. It will be inferior corneal fluorescein staining. We'll measure it at 2 weeks. So the measurement will be fairly quick. And as a result, we think we're now very well positioned to complete the remainder of the program and back an NDA submission. As for the first piece, the Type C meeting, there are several more technical items involved. I don't believe there's — I don't think the agency will have — I don't think we're raising any genuine questions regarding the design and the overall endpoints we're employing in MELODY-2 and MELODY-3 and the open label — pain, eye dryness, inferior corneal fluorescein staining. All of these are well-known endpoints and well-validated endpoints for use in these trials. The analyses we're conducting are quite straightforward. They're all ITT analyses. So no sub-group analysis is being planned.
Carl Spana
executiveI really don't see any issues there. So none of the questions are going to focus simply on whether what we plan to deliver is enough. And my expectation is they'll concur with that. Three large, well-controlled studies, I believe, will be more than adequate to back an NDA submission and their review. And beyond that, there are several — questions about manufacturing or whatever else that are more the kind of thing where — we need direction on what the next step ought to be, or they're not really — I'd put it this way, you could go with A or B. We just want to confirm which one you'd prefer. You want A, you want B. So nothing truly, in my view, major, just more direction regarding — what kind of data they're looking for in that area. So on the whole I anticipate a very productive meeting on the Type C. And as I mentioned, we're now planning to genuinely push the next group of studies ahead. I'm quite enthusiastic about the product. No, I appreciate those remarks. And I suppose I'll take that a bit further when it comes to possible endpoints for the upcoming study.
Carl Spana
executiveAnd you raised what I suppose is one of the more interesting aspects of dry eye development, where you mentioned looking at eight different signs — and would you want to stay with the same sign, since I know essentially you have to choose one in your discussions with the FDA. So how do you plan to handle that? On the sign side, it will be inferior corneal fluorescein staining. On the symptom side, we have plenty — there's flexibility for us there. Both pain and eye dryness — in fact, I believe eye dryness achieved the highest level of significance in MELODY-1. Either one is acceptable. I mean, one question we'll put to the agency is whether elevating eye dryness rather than pain would be acceptable. And it should be acceptable. Will they accept that in MELODY-1 as well? Just as we delivered in MELODY-2 and MELODY-3, will they accept that and have it serve as the endpoint in MELODY-1 too? And I think they will. But — where you're heading is that you'll likely have far more of the secondary endpoints be symptom based, because one of the things we do want to discuss with them is whether we hit all these symptoms again and as we replicate them.
Carl Spana
executiveIs it possible to put some of these on the label? Could we include some specific symptoms on the label? That, I think, would be one more differentiating feature.
Operator
operatorThat wraps up the question-and-answer portion, and nothing else is waiting in the queue. So at this point, I'll hand things back to Dr. Spana for any closing comments.
Carl Spana
executiveThank you. I appreciate everyone joining us for the Palatin Technologies conference call covering the third quarter of fiscal year 2024. Have a wonderful day — Steve and I are eager to bring you up to date on how we're doing, and we're really enthusiastic about the direction the company is headed and the milestones ahead of us over the rest of this year. So enjoy your day, and thanks again.
Operator
operatorThanks to all of you. That brings us to the end of today's conference call. At this point you're welcome to disconnect your phone lines, and we hope the rest of your day is wonderful. We appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.